MedTrace Logo

Transcatheter Aortic Valve Replacement With Extracorporeal Life System Support

NCT04160624 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-11-13

No results posted yet for this study

Summary

Transcatheter aortic valve replacement (TAVR) has a high risk and a high mortality rate in the treatment of aortic stenosis/regurgitation patients with cardiac insufficiency. The investigators aim to discuss the clinical efficacy of extracorporeal life support system(ECLS) during TAVR procedure in severe aortic lesion under very low ejection fraction (EF).

Conditions

  • Aortic Stenosis
  • Aortic Regurgitation
  • Heart Failure With Reduced Ejection Fraction

Interventions

PROCEDURE

transcatheter aortic valve replacement

Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Shiqiang Yu, M.D. PH.D. · The First Affiliated Hospital of Air Force Medicial University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04160624 on ClinicalTrials.gov